{
  "id": 1062,
  "lastUpdated": "2025-03-01T01:04:11.962Z",
  "agency": "House",
  "description": "Providing coverage for biomarker testing.",
  "introducedDate": "2025-01-13T08:00:00.000Z",
  "status": {
    "ts": "2025-01-13T08:00:00.000Z",
    "text": "First reading, referred to Health Care & Wellness."
  },
  "sponsors": [
    "Stonier",
    "Corry",
    "Parshley",
    "Thai",
    "Macri",
    "Ryu",
    "Leavitt",
    "Berry",
    "Reed",
    "Alvarado",
    "Callan",
    "Tharinger",
    "Fosse",
    "Simmons",
    "Davis",
    "Ormsby",
    "Reeves",
    "Bernbaum",
    "Donaghy",
    "Hill"
  ],
  "document": {
    "name": "1062",
    "description": "House Bill 1062",
    "url": {
      "ts": "2024-12-13T19:36:30.287Z",
      "text": "http://lawfilesext.leg.wa.gov/biennium/2025-26/Htm/Bills/House Bills/1062.htm"
    },
    "original": {
      "ts": "2024-12-13T19:36:30.287Z",
      "text": "<!DOCTYPE html ><html><body><div>H-0187.1</div><hr style=\"margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;\" /><div style=\"font-weight:bold;text-align:center;\">HOUSE BILL 1062</div><hr style=\"margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;\" /><table style=\"width:622px;margin-top:0.1in;\"><tr><td><div style=\"font-weight:bold;\">State of Washington</div></td><td><div style=\"font-weight:bold;\">69th Legislature</div></td><td><div style=\"font-weight:bold;\">2025 Regular Session</div></td></tr></table><div style=\"margin-top:0.1in;\"><span style=\"font-weight:bold;margin-right:0.25in;\">By</span><!-- field: Sponsors -->Representatives Stonier, Corry, Parshley, Thai, Macri, Ryu, Leavitt, Berry, Reed, Alvarado, Callan, Tharinger, Fosse, Simmons, Davis, Ormsby, Reeves, Bernbaum, Donaghy, and Hill<!-- field: --></div><div style=\"margin-top:0.1in;\"><span style=\"margin-right:0.25in;\">Prefiled 12/13/24.</span><span style=\"margin-right:0.25in;\">Read first time 01/13/25.</span><span style=\"margin-right:0.25in;\">Referred to Committee on Health Care &amp; Wellness.</span></div><div style=\"text-indent:0.5in;margin-top:0.5in;\"><!-- field: CaptionsTitles -->AN ACT Relating to coverage for biomarker testing; adding a new section to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43'>48.43</a> RCW; adding a new section to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=41.05'>41.05</a> RCW; and adding a new section to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=74.09'>74.09</a> RCW.<!-- field: --></div><div style=\"margin-top:0.25in;margin-bottom:0.25in;\">BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:</div><div style=\"margin-top:0.25in;text-indent:0.5in;\"><!-- field: BeginningSection --><span style=\"text-decoration:underline;\">NEW SECTION.</span><span>  </span><span style=\"font-weight:bold;padding-right:0.1in;\">Sec. 1.  </span>A new section is added to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43'>48.43</a> RCW to read as follows:<!-- field: --></div><div style=\"text-indent:0.5in;\"><!-- field: Text -->(1) For health plans issued or renewed on or after January 1, 2026, a health carrier shall include coverage for biomarker testing pursuant to the criteria established under subsection (2) of this section.</div><div style=\"text-indent:0.5in;\">(2) Biomarker testing must be covered for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when the test is supported by medical and scientific evidence including, but not limited to:</div><div style=\"text-indent:0.5in;\">(a) Labeled indications for tests approved or cleared by the United States food and drug administration or indicated tests for a drug approved by the United States food and drug administration;</div><div style=\"text-indent:0.5in;\">(b) Centers for medicare and medicaid services national coverage determinations or medicare administrative contractor local coverage determinations;</div><div style=\"text-indent:0.5in;\">(c) Nationally recognized clinical practice guidelines; or</div><div style=\"text-indent:0.5in;\">(d) Consensus statements.</div><div style=\"text-indent:0.5in;\">(3) Health carriers shall ensure coverage as required in subsection (2) of this section is provided in a manner that limits disruptions in care including the need for multiple biopsies or biospecimen samples.</div><div style=\"text-indent:0.5in;\">(4) For the purposes of this section:</div><div style=\"text-indent:0.5in;\">(a) \"Biomarker\" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention. Biomarkers include but are not limited to gene mutations or protein expression.</div><div style=\"text-indent:0.5in;\">(b) \"Biomarker testing\" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests, multiplex panel tests, and whole genome sequencing.</div><div style=\"text-indent:0.5in;\">(c) \"Consensus statements\" means statements that are:</div><div style=\"text-indent:0.5in;\">(i) Developed by an independent, multidisciplinary panel of experts utilizing a transparent methodology and reporting structure and with a conflict of interest policy;</div><div style=\"text-indent:0.5in;\">(ii) Aimed at specific clinical circumstances; and</div><div style=\"text-indent:0.5in;\">(iii) Based on the best available evidence for the purpose of optimizing the outcomes of clinical care.</div><div style=\"text-indent:0.5in;\">(d) \"Nationally recognized clinical practice guidelines\" means evidence-based clinical practice guidelines that:</div><div style=\"text-indent:0.5in;\">(i) Are developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy;</div><div style=\"text-indent:0.5in;\">(ii) Establish standards of care informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options; and</div><div style=\"text-indent:0.5in;\">(iii) Include recommendations intended to optimize patient care.</div><!-- field: --><div style=\"margin-top:0.25in;text-indent:0.5in;\"><!-- field: BeginningSection --><span style=\"text-decoration:underline;\">NEW SECTION.</span><span>  </span><span style=\"font-weight:bold;padding-right:0.1in;\">Sec. 2.  </span>A new section is added to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=41.05'>41.05</a> RCW to read as follows:<!-- field: --></div><div style=\"text-indent:0.5in;\"><!-- field: Text -->(1) A health plan offered to public employees and their covered dependents under this chapter issued or renewed on or after January 1, 2026, shall include coverage for biomarker testing pursuant to the criteria established under subsection (2) of this section.</div><div style=\"text-indent:0.5in;\">(2) Biomarker testing must be covered for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when the test is supported by medical and scientific evidence including, but not limited to:</div><div style=\"text-indent:0.5in;\">(a) Labeled indications for tests approved or cleared by the United States food and drug administration or indicated tests for a drug approved by the United States food and drug administration;</div><div style=\"text-indent:0.5in;\">(b) Centers for medicare and medicaid services national coverage determinations or medicare administrative contractor local coverage determinations;</div><div style=\"text-indent:0.5in;\">(c) Nationally recognized clinical practice guidelines; or</div><div style=\"text-indent:0.5in;\">(d) Consensus statements.</div><div style=\"text-indent:0.5in;\">(3) A health plan offered to public employees and their covered dependents shall ensure coverage as required in subsection (2) of this section is provided in a manner that limits disruptions in care including the need for multiple biopsies or biospecimen samples.</div><div style=\"text-indent:0.5in;\">(4) For purposes of this section, \"biomarker,\" \"biomarker testing,\" \"consensus statements,\" and \"nationally recognized clinical practice guidelines\" all have the same meaning as defined in section 1 of this act.</div><!-- field: --><div style=\"margin-top:0.25in;text-indent:0.5in;\"><!-- field: BeginningSection --><span style=\"text-decoration:underline;\">NEW SECTION.</span><span>  </span><span style=\"font-weight:bold;padding-right:0.1in;\">Sec. 3.  </span>A new section is added to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=74.09'>74.09</a> RCW to read as follows:<!-- field: --></div><div style=\"text-indent:0.5in;\"><!-- field: Text -->(1) Beginning January 1, 2026, the authority shall provide coverage under this chapter for biomarker testing pursuant to the criteria established under subsection (2) of this section.</div><div style=\"text-indent:0.5in;\">(2) Biomarker testing must be covered for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when the test is supported by medical and scientific evidence including, but not limited to:</div><div style=\"text-indent:0.5in;\">(a) Labeled indications for tests approved or cleared by the United States food and drug administration or indicated tests for a drug approved by the United States food and drug administration;</div><div style=\"text-indent:0.5in;\">(b) Centers for medicare and medicaid services national coverage determinations or medicare administrative contractor local coverage determinations;</div><div style=\"text-indent:0.5in;\">(c) Nationally recognized clinical practice guidelines; or</div><div style=\"text-indent:0.5in;\">(d) Consensus statements.</div><div style=\"text-indent:0.5in;\">(3) The authority shall ensure coverage as required in subsection (2) of this section is provided in a manner that limits disruptions in care including the need for multiple biopsies or biospecimen samples.</div><div style=\"text-indent:0.5in;\">(4) In administering this program, the authority shall seek any available federal financial participation under the medical assistance program, as codified at Title XIX of the federal social security act, or any other federal funding sources that are now available or may become available.</div><div style=\"text-indent:0.5in;\">(5) For purposes of this section, \"biomarker,\" \"biomarker testing,\" \"consensus statements,\" and \"nationally recognized clinical practice guidelines\" all have the same meaning as defined in section 1 of this act.</div><!-- field: --><div style=\"margin-top:0.1in;font-weight:bold;text-align:center;\">--- END ---</div></body></html>"
    },
    "summary": {
      "ts": "2024-12-13T19:36:30.287Z",
      "text": "<h3>Purpose</h3>\n<p>The purpose of this bill is to mandate health coverage for biomarker testing starting January 1, 2026. This bill aims to ensure that health plans cover biomarker testing for the diagnosis, treatment, management, and monitoring of diseases or conditions, as supported by scientific and medical evidence. It is designed to improve the continuity of patient care and reduce the need for multiple biopsies or biospecimen samples.</p>\n<h3>Key Provisions</h3>\n<h4>Coverage Requirements</h4>\n<ul>\n<li>Health plans issued or renewed on or after January 1, 2026, must cover biomarker testing under specified criteria.</li>\n<li>Coverage must include biomarker testing for diagnosis, treatment, management, or monitoring of a patient's disease, supported by:<ul>\n<li>Tests approved or cleared by the FDA.</li>\n<li>National coverage determinations by Medicare or local coverage determinations.</li>\n<li>Nationally recognized clinical practice guidelines.</li>\n<li>Consensus statements created by expert panels.</li></ul></li>\n</ul>\n<h4>Care Continuity</h4>\n<ul>\n<li>Health carriers are required to provide coverage in a way that minimizes disruptions in care, specifically avoiding the need for multiple biopsies or biospecimen samples.</li>\n</ul>\n<h4>Public Employee Plans</h4>\n<ul>\n<li>Public employee health plans are subject to the same coverage requirements for biomarker testing as private health plans.</li>\n</ul>\n<h4>State Authority</h4>\n<ul>\n<li>The state authority will provide coverage for biomarker testing under its program beginning January 1, 2026, ensuring adherence to the established criteria and minimizing care disruptions.</li>\n</ul>\n<h4>Federal Funding</h4>\n<ul>\n<li>The authority is encouraged to seek federal financial participation and funding sources to support these coverage requirements.</li>\n</ul>\n<p>This bill establishes comprehensive guidelines for the inclusion of biomarker testing in health insurance plans, aimed at enhancing medical care for patients and promoting evidence-based practices.</p>"
    }
  },
  "subDocuments": [],
  "keywords": {
    "ts": "2024-12-13T19:36:30.287Z",
    "text": "biomarker testing health coverage care continuity continuity patient care federal funding employee health plans diagnostic criteria quality standards"
  }
}